LabyRx Immuno-Oncology
LabyRx is a clinical-stage immuno-oncology company focused on developing next-generation therapeutic vaccines and antibody therapies to improve cancer treatment worldwide. Their flagship product, LabVax, is a synthetic peptide vaccine targeting adenocarcinomas, designed to harness the immune system to fight cancer with high precision and minimal side effects. The company is dedicated to advancing cancer immunotherapy through innovative platforms, clinical trials, and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
Products
Labyrinthin-derived synthetic peptide cancer vaccine (clinical-stage)
A clinical-stage synthetic peptide vaccine platform derived from a tumor-associated antigen designed to induce both antibody and T‑cell responses against adenocarcinoma tumors; developed for use alone or in combination with adjuvants and checkpoint inhibitors.
Labyrinthin-derived synthetic peptide cancer vaccine (clinical-stage)
A clinical-stage synthetic peptide vaccine platform derived from a tumor-associated antigen designed to induce both antibody and T‑cell responses against adenocarcinoma tumors; developed for use alone or in combination with adjuvants and checkpoint inhibitors.
Services
Collaborative planning and execution of early-stage oncology clinical trials with academic and national research centers, including regulatory coordination and patient enrollment strategies.
Development of assays to detect tumor-associated antigen expression for diagnostics, patient selection, and monitoring of therapeutic response.
In vitro and in vivo testing services including cell culture assays and patient-derived xenograft studies to evaluate therapeutic candidates prior to clinical development.
Collaborative planning and execution of early-stage oncology clinical trials with academic and national research centers, including regulatory coordination and patient enrollment strategies.
Development of assays to detect tumor-associated antigen expression for diagnostics, patient selection, and monitoring of therapeutic response.
In vitro and in vivo testing services including cell culture assays and patient-derived xenograft studies to evaluate therapeutic candidates prior to clinical development.
Expertise Areas
- Therapeutic cancer vaccine development
- Monoclonal antibody therapeutics
- Biomarker discovery and diagnostic assay development
- Early-stage oncology clinical trials (Phase I/II)
Key Technologies
- Synthetic peptide vaccine constructs
- Monoclonal antibody generation
- Immunoassays for antigen detection (diagnostic assays)
- Patient-derived xenograft (PDX) models
News & Updates
High Labyrinthin Expression is Associated with High PDL-1 Expression and Poor Prognosis in Patients with NSCLC, March 2024.
Multiple presentations on Labyrinthin as a diagnostic marker and therapeutic target, and clinical trials involving LabVax and pembrolizumab.
Describes the clinical trial of LabVax in combination with immune checkpoint inhibitors.
Labyrinthin: From bench-to-clinic as neo-and pan-adenocarcinoma target, July 2023.
Published in ASCO/Journal of Clinical Oncology 2023.
Study indicating labyrinthin as a key target for screening and treatment of adenocarcinomas.
High Labyrinthin Expression is Associated with High PDL-1 Expression and Poor Prognosis in Patients with NSCLC, March 2024.
Multiple presentations on Labyrinthin as a diagnostic marker and therapeutic target, and clinical trials involving LabVax and pembrolizumab.
Describes the clinical trial of LabVax in combination with immune checkpoint inhibitors.
Labyrinthin: From bench-to-clinic as neo-and pan-adenocarcinoma target, July 2023.
Published in ASCO/Journal of Clinical Oncology 2023.
Study indicating labyrinthin as a key target for screening and treatment of adenocarcinomas.